New call for projects for treatments that could be repurposed to treat epidermolysis bullosa (EB), a life-changing and currently incurable rare skin dise...
Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period. The interest rate for a draw is 1% plus the rate paid on cert...
Co-led by William Abecassis, Braven’s Managing Partner, and Dr. Sean Khozin, Senior Life Sciences & Healthcare Partner, the Unit supports the fir...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definit...
To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate ...
During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404...
Adds production capacity to further provide customers with highly purified reagents for quality control and testing Major investment at company’s ...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia AstraZeneca h...
AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has raised $3 milli...
Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the m...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precis...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
© 2025 Biopharma Boardroom. All Rights Reserved.
